Trial Profile
Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Palmoplantar pustulosis
- Focus Therapeutic Use
- 09 Aug 2011 New trial record